Adult Growth Hormone Deficiency: Current Concepts

Izumi FUKUDA, Naomi HIZUKA, Toko MURAOKA, and Atsuhiro ICHIHARA

1Department of Medicine II, Tokyo Women’s Medical University, Tokyo

Abstract

The clinical syndrome of adult growth hormone deficiency (AGHD) was widely recognized in the 1980s. In this review, we first describe the clinical features and diagnosis of AGHD and then state the effects of growth hormone (GH) therapy for these patients. The main characteristics of AGHD are abnormal body composition, dyslipidemia, insulin resistance, and an impaired quality of life (QoL) due to decreased psychological well-being. For diagnosing AGHD, the international consensus guidelines have suggested that an insulin tolerance test (ITT) is the gold standard, but in Japan, the growth hormone releasing peptide-2 (GHRP-2) test is available and is recommended as a convenient and safe GH stimulating test. The cut-off for diagnosing severe AGHD is a peak GH concentration of 9 g/L during the GHRP-2 test. Since 2006, GH therapy has been approved for Japanese patients with severe AGHD. For adults, GH replacement therapy should be initiated at a low dose (3 g/kg body weight/day), followed by individualized dose titration while monitoring patients’ clinical status and serum insulin-like growth factor-I (IGF-I) concentrations. A variety of favorable effects of GH replacement have been indicated; however, it has not yet been established fully whether there is a direct effect of GH treatment on reducing mortality.

Key words: dyslipidemia, growth hormone releasing peptide-2 test, insulin-like growth factor-I, non-alcoholic fatty liver disease

Introduction

Growth hormone (GH) is classically linked with linear growth during childhood. However, in 1962, Raben reported the improvement in the well-being of a 35-year-old woman with hypopituitarism who had been treated with pituitary-derived GH. This suggested that GH might continue to play an important role throughout life in various metabolic actions and influence one’s psychological state. In the 1980s, recombinant human GH (rhGH) became widely available and its effects in adults were extensively studied. The first double-blind, randomized, placebo-controlled study assessing GH treatment in adult GH deficiency (AGHD) was performed in 1989, and various favorable effects of GH replacements were confirmed. Since 2006, GH therapy has been approved for Japanese patients with severe AGHD. In this review, we describe the clinical features, diagnosis, and effects of GH treatment in patients with AGHD.

Causes of AGHD

Table 1 shows the causes of AGHD. GH is usually the first anterior pituitary hormone that is adversely affected by organic lesions in the hypothalamus and/or pituitary. Therefore, the probability of identifying GH deficiency (GHD) is generally higher in patients with multiple pituitary hormone deficiencies and its resultant pathologies. The most common cause of GHD during adulthood is a non-functioning pituitary adenoma and its treatment.

Patients Who Should Be Evaluated for AGHD

An evaluation for AGHD is considered for patients who exhibit evidence of hypothalamic-pituitary disease, and for whom there is an intent to treat. Testing patients who have other pituitary hormone deficiencies, a history of cranial irradiation, a traumatic brain injury, or a subarachnoid hemorrhage is also recommended by the international guideline from the Growth Hormone Research Society. It is also recommended for those adults who have experienced childhood-onset GHD, regardless of whether they fulfill the criteria for severe GHD, that they be retested as adults unless they have a known mutation or have acquired irreversible structural pituitary lesions before long-term GH replacement was commenced.
How to Diagnose AGHD

I. Clinical signs and symptoms of AGHD

In adults suspected of having GHD, there is no specific clinical sign that offers the same measure of diagnostic "certainty" as the growth retardation that occurs in children. Patients with AGHD can exhibit a variety of clinical signs including increased fat mass, particularly fat distributed in the abdominal region, decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance. AGHD may also be associated with altered cardiac structure and function, and reduced physical performance. As a result of such symptoms, patients can subsequently experience and report a reduced quality of life (QoL).

Several epidemiological studies have indicated an associated increased mortality risk in patients with hypopituitarism, particularly when all pituitary hormones except GH were replaced; however, the increase in mortality may in part be attributed to the inappropriate replacement of other pituitary hormones, or a history of radiotherapy localized to the hypothalamic-pituitary region. The standardized mortality rate for individuals with AGHD has been shown to be about 1.8 compared to the general population, and the mortality linked to cardiovascular complications appears to be increased.

II. GH stimulation test

International consensus guidelines have suggested that the insulin tolerance test (ITT) is the gold standard test for diagnosing AGHD. The reliability of the ITT, as a provocative test with a cut-off diagnostic concentration of 5.1 g/L, was demonstrated by results indicating 96% sensitivity and 92% specificity when evaluated by the receiver operator characteristic (ROC) curve analysis. According to the current guidelines, the cut-off for a biochemical diagnosis of AGHD during an ITT is a peak GH concentration that is equal to or less than 3 g/L. However, the ITT must be performed under careful medical management in an experienced endocrine unit and is contraindicated for several clinical conditions including a history of seizures and/or ischemic heart disease. It should also be noted that false-positive results may occur in patients who are severely obese.

In Japan, Chihara et al. proposed the usefulness of the GH-releasing peptide-2 (GHRP-2) test for evaluating GH secretory status. For diagnosing AGHD, a GH cut-off value of 15 g/L with a GHRP-2 test corresponded with a value of 3 g/L for the ITT, whereas severe AGHD was diagnosed using a cut-off value of 9 g/L for the peak GH level in GHRP-2 test. The GHRP-2 test is considered to be a convenient and safe diagnostic test for AGHD. Among other classical provocative tests, the arginine test and glucagon test have been considered as alternatives, although they have less discriminatory power than the ITT.

III. Serum IGF-I levels

A considerable overlap has been shown to exist between circulating insulin-like growth factor-I (IGF-I) concentrations in healthy subjects, matched for age and sex, and IGF-I concentrations in patients with AGHD, even in those patients classified as having severe AGHD which was confirmed by a GH stimulating test. Therefore, normal IGF-I levels cannot be excluded from a diagnosis of AGHD, and GH stimulating test should be considered for patients who have an evidence or a strong clinical suspicion of hypothalamic-pituitary disease, even if circulating
IGF-I levels are within the normal range. On the contrary, the presence of low IGF-I levels in patients with hypopituitarism, which is associated with more than three pituitary hormone deficiencies, is highly indicative of the existence of GHD.

**Treatment Aims for AGHD**

The aim of GH replacement therapy is to treat the signs and symptoms of GHD by correcting the metabolic abnormalities and impaired QoL associated with AGHD.

**GH Dosing Titration**

Determining an appropriate GH replacement dose is a relatively more challenging task when treating adults with GHD as opposed to children with GHD because the efficacy of administered GH is overtly reflected in linear growth in children. The tolerance of adults for GH is lower than that of children, and the individual responsiveness to GH varies according to many factors such as age, age at onset of GHD, sex, and adiposity. In general, women require more GH per kilogram of body weight than men, younger patients require more GH than older patients, and adult patients who had childhood-onset require more GH than adult-onset GHD to obtain an equivalent clinical response.

In healthy subjects, similar IGF-I levels depend on a higher GH secretion in women. By a similar mechanism, the sex-related differences in GH dose requirements occur because estrogen modulates hepatic IGF-I generation in women more than it does in males. Taking these things into consideration, the GH dosing guidelines issued by the Growth Hormone Research Society recommend the following:6)

- GH replacement therapy should start with a low dose, especially in older individuals (0.1 mg/day), administered as daily subcutaneous injections in the evening.
- GH dosages should be increased gradually and individualized, on the basis of clinical and biochemical responses, no more frequently than at monthly intervals.
- Incremental dose increases should be between 0.1 mg/day and 0.2 mg/day.
- Clinical status and serum IGF-I levels should be monitored.
- The GH maintenance dose should seldom exceed 1.0 mg/day.

It is recommended that GH replacement dose should not be based on body weight; individualized dose titrations should follow to optimize the potential for beneficial effects with a minimum of side effects.13)

Serum IGF-I is the most useful biological marker for monitoring GH dose titration. To adjust a dose of GH, several authors recommend aiming for IGF-I concentrations in the upper half of the reference range,14,15) but it is suggested to not exceed the upper limit of the normal range by more than two standard deviations (SDs).

In female patients receiving estrogen replacement therapy, a higher dose of GH is typically required when oral versus transdermal estrogen is administered.16) Oral estrogen more prominently impairs the modulatory effect of GH on hepatic IGF-I production than does transdermal estrogen, primarily because a higher concentration of estrogen passes through the liver after oral administration.

**Effects of GH Replacement**

**I. Body composition**

GH and IGF-I play a key role in maintaining normal body composition in adults. Adult patients with untreated GHD have an abnormal body composition with an increase in their total and visceral fat mass, and a decrease in their lean body mass and total body water. Compared to age-matched subjects, the body fat mass of adult patients with GHD was shown to be about 7% higher and was associated with insulin resistance and an increased risk for cardiovascular complications.17) According to more than 50 randomized and controlled trials that compared the effects of GH to a placebo treatment in adults with GHD, GH replacement was associated with a significant reduction in both body weight (2.3 kg) and body fat (2.6 kg), and an increase in lean body mass without significant changes in their body mass index.17) A systematic review of the effects of long-term GH replacement (> 5 years) on body composition in patients with AGHD confirmed an associated consistent increase in lean body mass and a decrease in body fat mass; however, the effects on body mass index (BMI) were conflicting.16)

**II. Bone metabolism**

Severe AGHD has been associated with low bone mineral density (BMD) and low bone mineral content (BMC), likely attributable to low bone turnover and delayed mineralization, which has been shown to improve following GH treatment.19,20) The BMD of older adult patients with GHD seems to be less adversely affected. Toogood et al. reported that there was no difference in the BMD of patients with AGHD who were older than 60 years compared to age-matched subjects without AGHD.21) The effects
of GH replacement on bone metabolism have been shown to vary depending on the duration of GH therapy. According to the results of four studies that analyzed the effects of long-term GH therapy on bone metabolism in more than 300 patients with AGHD, BMD declined after the initiation of GH as a result of increased bone resorption. However, these same studies all reported a subsequent increase in BMD within the first year of treatment; the increase reached a plateau phase that was maintained according to observations made after 5 years.18

III. Lipid metabolism, inflammatory markers, and atherosclerosis findings

Low-density lipoprotein-cholesterol (LDL-C) and triglyceride levels increase in patients with AGHD. Similarly, serum markers of inflammation, such as interleukin 6 (IL-6) and C-reactive protein (CRP), become elevated in patients with AGHD.13 Carotid intima-media thickness (IMT), which is a biomarker for the risk of myocardial infarction and stroke, also increased in patients with AGHD. GH replacement was associated with a significant improvement in LDL-C and high-density lipoprotein-cholesterol (HDL-C), but no change in triglyceride status was evident.20 A study has investigated whether GH therapy can provide a benefit to patients with severe AGHD by lowering LDL-C. This study assessed whether any additional benefit could be derived when GH therapy was added to statin (HMG-CoA reductase inhibitors) therapy versus the benefit achieved by administering statins alone.19,22 The study results revealed that GH administration achieved a significant additional improvement in LDL-C, suggesting that not only statins, but also statins in combination with GH therapy, can provide clinically meaningful benefits in the management of patients with AGHD and associated dyslipidemia. Evidence also exists to show that carotid IMT is rapidly improved with GH replacement; it decreased up to 18% after long-term therapy, and circulating IL-6 and CRP concentrations also decreased.20 It is not clear whether the reduction in inflammation markers is due to a direct effect of GHs on the immune system, or if inflammation is indirectly mediated by an improvement in body composition.13

IV. Quality of life

Reduced QoL and well-being resulting from low energy levels, social isolation, and increased emotional stress are well-known psychological effects of AGHD.19 In general, QoL seems to improve during long-term GH therapy. The positive effects on QoL have been observed within the first year of treatment and have been maintained thereafter.20 Japanese patients with AGHD reported a decreased QoL, as evaluated by the Short Form (36) Health Survey (SF-36), but significant effects of 24 weeks of GH replacement on QoL were not observed.23

V. Fatty liver disease

Several clinical studies have suggested that non-alcoholic fatty liver disease (NAFLD), or its progressive condition referred to as non-alcoholic steatohepatitis (NASH), is frequently observed in patients with AGHD.24 These co-morbidities have been improved by GH therapy, suggesting that the deficit of GH contributes to steatosis and fibrosis in the liver.24 Recently, Nishizawa et al. reported that a GH-deficient rat model developed NASH, and not only the administration of GH, but also IGF-I prevented the development of liver disease in this rodent model. It was presumed that IGF-I plays an essential role in the liver by improving mitochondrial function and reducing oxidative stress.25

The benefits of GH therapy in patients with AGHD are listed in Table 2.26 The cost of GH treatment is

| Clinical features of AGHD | Benefits of GH replacement |
|--------------------------|-----------------------------|
| Abnormal body composition |                             |
| Increased fat mass       | Decreased fat mass           |
| Decreased lean body mass | Increased lean body mass     |
| Decreased BMD            | Increased BMD following an initial < 6 month decrease |
| Atherosclerosis risk factors |                                  |
| Dyslipidemia             | Decreased LDL-C              |
|                         | Increased HDL-C              |
|                         | Unchanged triglycerides      |
| Increased inflammatory markers |                                    |
| IL-6, CRP                | Decreased IL-6 and CRP       |
| Carotid IMT              | Decreased carotid IMT        |
| Development of NAFLD/NASH | Improved fatty liver disease |
| Decreased QoL            | General improvement in QoL    |
| Increased mortality      | Unknown effect on mortality  |

*Table modified in part from Hoffman.26 AGHD: adult growth hormone deficiency, BMD: bone mineral density, CRP: C-reactive protein, GH: growth hormone, HDL-C: high-density lipoprotein-cholesterol, IL-6: interleukin 6, IMT: intima-media thickness, LDL-C: low-density lipoprotein cholesterol, NAFLD: non-alcoholic fatty acid disease, NASH: non-alcoholic steatohepatitis, QoL: quality of life.

Neurol Med Chir (Tokyo) 54, August, 2014
relatively high. Therefore, long-term survey of efficacy and safety of GH replacement therapy including whether GH improves cardiovascular complications throughout the life and reduce mortality in adults with GH deficiency might be required in order to clarify more about cost-effectiveness of GH therapy.

**Side Effects of GH**

The most common side-effects of GH therapy are edema and arthralgia caused by GH-associated fluid retention. At present, there is insufficient evidence to suggest that GH replacement increases the risk of developing diabetes mellitus, at least in patients in the normal weight BMI category of 18.5–24.9 kg/m²; however, a reasonable strategy may be to start patients with AGHD on a low dose of GH if they present with a higher than normal BMI. Based on the observation of more than a thousand patients with AGHD, the likelihood of an increased risk for the recurrence and re-growth of hypothalamus-pituitary tumors was not determined in adults. In this report, Abs et al. also reported that there was no recurrence in 127 GH-treated adult patients with craniopharyngioma. Recently, several studies were performed whether GH replacement therapy affects on a tumor recurrence or increase in size of pituitary or central nervous system tumors. In 2005, Chung et al. reported a case of a 54-year-old patient with a germ cell tumor who required a suspension of GH therapy because of tumor recurrence. Hatrick et al. reported that there was no statistically significant differences in pituitary adenoma re-growth rate between GH treated group and controls. Olsson et al. investigated tumor progression in craniopharyngioma. The 10-year tumor progression free survival rate (PFSR) was 85% for the GH treatment group and 65% for the control group and they concluded that GH replacement did not affect the PFSR in patients with craniopharyngioma. Regarding an effect of long-term GH therapy on tumor recurrence, two studies reported 11 cases of tumor recurrence among 23 prospective studies with GH therapy duration ranging from 5 years to 15 years that were reviewed by Appelman-Dijkstra et al. One of those study concluded that the recurrence rate appeared to be no higher compared to control group; though, there was a lack of control data in the other study.

Because of its growth promoting effect, the influence of GH administration on cancer risk has been extensively studied. To date, children and adults treated with GH do not appear to have an increased cancer risk compared to general population. Of course, long-term surveillance of a large population is required continuously and it is important to maintain serum IGF-I levels during GH therapy within age-matched normal range for avoiding GH excess.

**Conclusion**

In this review, the clinical features and the diagnosis of AGHD are discussed, as well as the GH treatment guidelines that included a reference to their efficacy and safety. A severe GH deficit causes various metabolic abnormalities in addition to an impaired QoL due to decreased psychological well-being. GH dosing regimens should be individualized because of the distinct individual differences in terms of patients’ responsiveness to GH. GH therapy has proven to be beneficial for many patients with AGHD. The long-term clinical efficacy of GH replacement, including such factors as its ability to reduce cardiovascular events and its potential effects on the mortality of patients with AGHD are still largely unknown, and therefore the long-term clinical efficacy of GH replacement remain issues deserving future attention.

**Acknowledgment**

This work was supported in part by a research grant from the Ministry of Health, Labor, and Welfare, Japan.

**Conflicts of Interest Disclosure**

The authors declare no conflicts of interest.

**References**

1) Raben MS: Growth hormone. 2. Clinical use of human growth hormone. *N Engl J Med* 266: 82–86 concl, 1962
2) Salomon F, Cuneo RC, Hesp R, Sönksen PH: The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. *N Engl J Med* 321: 1797–1803, 1989
3) Jørgensen JO, Pedersen SA, Thuesen L, Jørgensen J, Ingemann-Hansen T, Skakkebaek NE, Christiansen JS: Beneficial effects of growth hormone treatment in GH-deficient adults. *Lancet* 1: 1221–1225, 1989
4) Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML; Endocrine Society: Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. *J Clin Endocrinol Metab* 96: 1587–1609, 2011
5) Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML; Endocrine Society's Clinical Guidelines Subcommittee, Stephens PA: Evaluation and treatment of adult growth hormone deficiency:
an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 91: 1621–1634, 2006
6) Ho KK; 2007 GH Deficiency Consensus Workshop Participants: Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. *Eur J Endocrinol* 157: 695–700, 2007
7) Sönksen PH, Christiansen JS: Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency. Growth Hormone Research Society. *Growth Horm IGF Res* 8(Suppl B): 89–92, 1998
8) Rosén T, Bengtsson BA: Premature mortality due to cardiovascular disease in hypopituitarism. *Lancet* 336: 285–288, 1990
9) Tomlinson JW, Holden N, Hills RK, Wheatley K, Clayton RN, Bates AS, Sheppard MC, Stewart PM: Association between premature mortality and hypopituitarism. West Midlands Prospective Hypopituitary Study Group. *Lancet* 357(9254): 425–431, 2001
10) Biller BM, Samuels MH, Zagar A, Cook DM, Arafa SM, Bonert V, Stavrou S, Kleinberg DL, Chipman JJ, Hartman ML: Sensitivity and specificity of six tests for the diagnosis of adult GH deficiency. *J Clin Endocrinol Metab* 87: 2067–2079, 2002
11) Chihara K, Shimatsu A, Hizuka N, Tanaka T, Seino Y, Katofor Y, KP-102 Study Group: A simple diagnostic test using GH-releasing peptide-2 in adult GH deficiency. *Eur J Endocrinol* 157: 1927, 2002
12) Lissett CA, Jönsson P, Monson JP, Shalet SM; KIMS International Board: Determinants of IGF-I status in a large cohort of growth hormone-deficient (GHD) subjects: the role of timing of onset of GHD. *Clin Endocrinol (Oxf)* 59: 773–778, 2003
13) Nilsson AG, Svensson I, Johansson G: Management of growth hormone deficiency in adults. *Growth Horm IGF Res* 17: 441–462, 2007
14) Drake WM, Coyte D, Camacho-Hübner C, Jivanji NM, Kaltasas G, Wood DF, Trainer PJ, Grossman AB, Besser GM, Monson JP: Optimizing growth hormone replacement therapy by dose titration in hypopituitary adults. *J Clin Endocrinol Metab* 83: 3913–3919, 1998
15) Mukherjee A, Monson JP, Jönsson P, Trainer PJ, Shalet SM; KIMS International Board: Seeking the optimal target range for insulin-like growth factor I during the treatment of adult growth hormone disorders. *J Clin Endocrinol Metab* 88: 5865–5870, 2003
16) Filipsson J, Johannsson G: GH replacement in adults: interactions with other pituitary hormone deficiencies and replacement therapies. *Eur J Endocrinol* 161(Suppl 1): S85–S95, 2009
17) Hazem A, Elamin MB, Bancos I, Malaga G, Prutsky G, Domecq JP, Elraiyah TA, Abu Elnour NO, Prevost Y, Almandoz JP, Zeballos-Palacios C, Velasquez ER, Erwin PJ, Natt N, Montori VM, Murad MH: Body composition and quality of life in adults treated with GH therapy: a systematic review and meta-analysis. *Eur J Endocrinol* 166: 13–20, 2012
18) Appelman-Dijkstra NM, Claessen KM, Roelfsema F, Pereira AM, Biermasz NR: Long-term effects of recombinant human GH replacement in adults with GH deficiency: a systematic review. *Eur J Endocrinol* 169: R1–R14, 2013
19) Thomas JD, Monson JP: Adult GH deficiency throughout lifetime. *Eur J Endocrinol* 161(Suppl 1): S97–S106, 2009
20) Drake WM, Rodríguez-Arnao J, Weaver JU, James IT, Coyte D, Spector TD, Besser GM, Monson JP: The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. *Clin Endocrinol (Oxf)* 54: 525–532, 2001
21) Toogood AA, Adams JE, O’Neill PA, Shalet SM: Elderly patients with adult-onset growth hormone deficiency are not osteopenic. *J Clin Endocrinol Metab* 82: 1462–1466, 1997
22) Monson JP, Jönsson P, Koltowska-Häggström M, Kourides I: Growth hormone (GH) replacement decreases serum total and LDL-cholesterol in hypopituitary patients on maintenance HMG CoA reductase inhibitor (statin) therapy. *Clin Endocrinol (Oxf)* 67: 623–628, 2007
23) Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A: Efficacy and safety of growth hormone (GH) in the treatment of adult Japanese patients with GH deficiency: a randomised, placebo-controlled study. *Growth Horm IGF Res* 16: 132–142, 2006
24) Takahashi Y: Essential roles of growth hormone (GH) and insulin-like growth factor-I (IGF-I) in the liver. *Endocr J* 59: 955–962, 2012
25) Nishizawa H, Takahashi M, Fukuoka H, Iguchi G, Kitazawa R, Takahashi Y: GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model. *Biochem Biophys Res Commun* 423: 295–300, 2012
26) Hoffman AR: Treatment of the adult growth hormone deficiency syndrome: directions for future research. *Growth Horm IGF Res* 15(Suppl A): 48–52, 2005
27) Svensson J, Bengtsson BA: Safety aspects of GH replacement. *Eur J Endocrinol* 161(Suppl 1): S65–S74, 2009
28) Abs R, Bengtsson BA, Hernberg-Stähl E, Monson JP, Tauber JP, Wilton P, Wüster C: GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. *Clin Endocrinol (Oxf)* 50: 703–713, 1999
29) Chung TT, Drake WM, Evanson J, Walker D, Plowman PN, Chew SL, Grossman AB, Besser GM, Monson JP: Tumour surveillance imaging in patients with extrapituitary tumours receiving growth hormone replacement. *Clin Endocrinol (Oxf)* 63: 274–279, 2005

I. Fukuda et al.

*Neurol Med Chir (Tokyo)* 54, August, 2014
30) Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL: Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? *Eur J Endocrinol* 146: 807–811, 2002

31) Olsson DS, Buchfelder M, Wiendieck K, Kremenevskaja N, Bengtsson BÅ, Jakobsson KE, Jarfelt M, Johansson G, Nilsson AG: Tumour recurrence and enlargement in patients with craniopharyngioma with and without GH replacement therapy during more than 10 years of follow-up. *Eur J Endocrinol* 166: 1061–1068, 2012

32) Spielhagen C, Schwahn C, Möller K, Friedrich N, Kohlmann T, Moock J, Koltsowsa-Häggström M, Nauck M, Buchfelder M, Wallaschofski H: The benefit of long-term growth hormone (GH) replacement therapy in hypopituitary adults with GH deficiency: results of the German KIMS database. *Growth Horm IGF Res* 21: 1–10, 2011

33) van der Klaauw AA, Romijn JA, Biermasz NR, Smit JW, van Doorn J, Dekkers OM, Roelfsema F, Pereira AM: Sustained effects of recombinant GH replacement after 7 years of treatment in adults with GH deficiency. *Eur J Endocrinol* 155: 701–708, 2006

34) Jenkins PJ, Mukherjee A, Shalet SM: Does growth hormone cause cancer? *Clin Endocrinol (Oxf)* 64: 115–121, 2006

**Address reprint requests to:** Izumi Fukuda, MD, PhD, Department of Medicine II, Tokyo Women’s Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.

*e-mail*: izumif@endm.twmu.ac.jp

*Neurol Med Chir (Tokyo)* 54, August, 2014